Affected rare diseases face many obstacles in our health care system. hurdles in our health care system. As there is often a lack of research, therapies and medicines, treatments for rare diseases are often limited or inaccessible. accessible. This is exacerbated by the fact that coverage by health insurers is by health insurance companies is usually unclear.

In Switzerland, it is estimated that around 6-8 percent of the population is affected by rare diseases. A significant part of the population does not have sufficient access to medical services. access to medical services. As a society, we are therefore increasingly faced with the how we, as a collective, can promote the appropriate and effective treatment of rare treatment of rare diseases. This panel discussion will address this question from a medical and legal perspective.

Panel

• Brigitte Tag, Faculty of Law, University of Zurich, Chairwoman of the Steering Committee of the University Competence Centre Medicine – Ethics – Law Helvetiae, Deputy Director of the UFSP ITINERARE
• Nikola Biller-Andorno, Faculty of Medicine University of Zurich, Vice Dean for Innovation and Digitalization, Member of the Steering Committee of the University Centre of Competence Medicine – Ethics – Law Helvetiae, Deputy Director of the UFSP ITINERARE
• Alfred Wiesbauer, Vice-President ProRaris
• Beat Rauber, Patent attorney with a major pharmaceutical company

Moderation
Andreas Schürer, Owner and CEO rivedia.com